Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 12/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13384775 | 0.85 | KDM4E (0.40) | TDP2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL13384791 | 0.85 | KDM4E (0.41) | TDP2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL13384798 | 0.83 | KDM4E (0.47) | KDM4EALDH1A1GAAHPGDESR1 | |
| SCHEMBL13384765 | 0.83 | KDM4E (0.45) | TDP2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL14222642 | 0.80 | TDP2 (0.41) | TDP2MIFCA9ESR1ESR2 | |
| SCHEMBL13384781 | 0.78 | CHEK1 (0.38) | TDP2KDM4EALDH1A1GAAHPGD | |
| SCHEMBL13384706 | 0.78 | ALDH1A1 (0.40) | TDP2ALDH1A1GAAMIFCA9 | |
| SCHEMBL13384730 | 0.77 | TDP2 (0.42) | TDP2KDM4EALDH1A1GAAMIF | |
| SCHEMBL13384788 | 0.77 | PDE4D (0.42) | KDM4EALDH1A1GAAHPGDESR1 | |
| SCHEMBL13384764 | 0.77 | KDM4E (0.35) | KDM4EALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | TIBOTEC BVBA (BE) | 2010-04-08 | — | — | US | disclosed |
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | TIBOTEC BVBA (BE) | 2010-04-08 | — | — | US | disclosed |
| WO-2008037784-A1 | QUINOLINONE DERIVATIVES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087649-A1 | QUINOLINONE DERIVATIVES | CHRM1, CYP2C8, CCR8 | TDP2 3082/4885KDM4E 2122/4885ALDH1A1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.